ResMed
- Market cap
- 31.78B
- P/E (TTM)i
- 21.67
- P/Bi
- 4.83
- EPSi
- 10.43
- Div yieldi
- 1.06%
- 52W posi
- 48%
Anonymous reader poll. Unscientific, not investment advice.
Shares of ResMed closed at 225.98, up 2.40%. That leaves the company valued at approximately 31.78B, the #644 most valuable US-listed company we track. Valuation-wise, the P/E sits at 21.20, 41% below the five-year average of 35.76. The stock also carries a trailing dividend yield of 1.06%. The 13 analysts covering the stock are, on balance, at Buy, targeting an average of 245.90 (+9%). Over the past year the stock has ranged from 179.75 to 275.42; it now sits 48% up that band.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 weeks.
- Its last 4 Sell calls were followed by a 4% average decline over the next quarter.
- Recent price momentum is -8.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 9.8% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation B-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 21.4x | Better than 44% |
| Forward P/E | 19.4x | Better than 44% |
| Price / Sales | 5.6x | Better than 24% |
| P/E vs own 5-yr range | 6th pctl | Better than 90% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 10.2% | Better than 65% |
| Net income CAGR (3Y) | 19.3% | Better than 73% |
| Free cash flow CAGR (3Y) | 42.8% | Better than 84% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 61.1% | Better than 76% |
| Operating margin | 33.8% | Better than 89% |
| Net margin | 26.9% | Better than 85% |
| Return on equity | 24.3% | Better than 74% |
| Return on invested capital | 21.4% | Better than 87% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 1.7% | Better than 59% |
| 6-month return | -0.8% | Better than 38% |
| 12-month return (ex latest month) | -18.0% | Better than 15% |
| Distance below 52-week high | 19.1% | Better than 49% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.1x | Better than 83% |
| Debt to assets | 9.2% | Better than 79% |
| Interest coverage | 28.7x | Better than 84% |
| Free cash flow / net income | 106.9% | Better than 45% |
Analyst View D
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 38.5% | Better than 18% |
| Upside to average target | 10.3% | Better than 17% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 220.69
- Open
- 222.27
- Day range
- 221.83 - 228.75
- Avg price
- 226.33
- Volume
- 1.13M
- Turnover
- 255.40M
- Turnover ratei
- 0.81%
- Volume ratioi
- 1.08
- Amplitudei
- 3.14%
- 52-week rangei
- 179.75 - 275.42
Valuation
- P/Ei
- 21.67
- P/E (TTM)i
- 21.67
- P/Bi
- 4.83
- EPSi
- 10.43
- Book value / shi
- 46.83
- Net profit
- 1.47B
- Net assets
- 6.59B
Share structure
- Market cap
- 31.78B
- Float capi
- 31.58B
- Shares out
- 140.64M
- Float sharesi
- 139.73M
Dividend & listing
- Div yield (TTM)i
- 1.06%
- Dividend (TTM)
- 2.40
- Listing date
- 1970-01-01
17.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-187.49M net over the window
Short interest
- Shares short
- 14.20M
- % of floati
- 9.85%
- Days to coveri
- 11.74
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of ResMed (RMD)?
ResMed last traded at 225.98. The quote on this page refreshes every few seconds while US markets are open.
What is ResMed's market cap?
About 31.78B.
What is the P/E ratio of ResMed?
The trailing twelve-month P/E is 21.67, below its own 5-year average of 35.76 — toward the bottom of its historical range (5.99% percentile). See the Valuation tab for the full history.
Does ResMed pay a dividend?
Yes. The trailing dividend yield is 1.06%. The 2025 payout was up 11.9% from 2024. See the Dividends tab for the full payment history.
Is ResMed a buy according to analysts?
The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 245.90, which implies 8.8% upside from the current price. This is not investment advice.
What is ResMed's StockVane Quant Rating?
The StockVane Momentum strategy currently rates ResMed a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 03:31:56 · For reference only, not investment advice and not tailored to your situation.